The 10 most common tumor entities (according to the WHO).
Conditions
Interventions
Group 1: LLM evaluation (HemOncBot): retrospective generation of therapy recommendations, based on current Oncopedia and ESMO guidelines, for tumor board cases of the last two years (from 01/01/2023)
Sponsors
Deutsches Krebsforschungszentrum (DKFZ)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ESMO and Onkopedia guidelines from 01/2020 (and more recent) are included in HemOncBot. The experts for evaluating the cases are licensed specialists in hematology and oncology who are currently practicing clinically in Germany. A university position or professorship is not required. The prerequisite is regular participation in interdisciplinary tumor boards as well as practical experience in guideline-based treatment decisions for oncology patients.
Exclusion criteria
Exclusion criteria: Tumor board cases with incomplete or non-standardized documented data, lack of pseudonymization, or outside the defined period (January 1, 2023 – November 1, 2025) are excluded. Also excluded are cases with rare or undefined tumor entities for which no current ESMO or Onkopedia guidelines exist (from January 2020 onwards), as well as cases with deliberately guideline-deviating or experimental treatment decisions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adherence to guidelines, accuracy/correctness of therapy recommendations | — |
Countries
Germany
Contacts
Public ContactTitus J. Brinker
Deutsches Krebsforschungszentrum (DKFZ), Abteilung für Digitale Prävention, Diagnostik und Therapiesteuerung
Outcome results
None listed